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of quercetin-rich and quercetin-poor onion therapy. At all three time points, a medical interview was conducted along with an assessment of vital signs, hematological and biological variables, and body composition. Additionally, the study partners completed the Japanese version of the Neuropsychiatric Inventory Questionnaire (NPI-Q-J). For the study, we asked subjects to consume 10 g per day of either the active onion powder containing 60 mg of quercetin or a placebo onion powder not containing quercetin. This intake was determined 1) in consideration of a previous trial [28] , which estimated the daily quercetin intake in Hokkaido, Japan, to be approximately 16 mg/day (ranging from 0.5 to 56.8 mg/day) [27] and 2) in consideration of the amount that the subjects could easily ingest each day during the clinical trial (approximately 83 g of raw onions/day). During the course of the study, the subjects were asked to not change their daily activities including food consumption, medications, and exercise routines. However, they were asked to limit their intake of quercetin-containing food, such as other onions or teas, beginning 1 week before the start of the study (as a washout period to reduce the effect of dietary quercetin) until the end of the study. Primary outcomes were MMSE and cognitive impairment rating scale scores. Secondary outcomes included lipid metabolism [total cholesterol (TC) levels, high-density lipoprotein cholesterol (HDL-C) levels, low-density lipoprotein cholesterol (LDL-C) levels, and triglyceride (TG) levels], glucose metabolism [blood glucose (BG) levels and hemoglobin A1c 
Preparation of test food
The quercetin-rich onion cultivars 'Quergold' and 'Sarasara-gold' used for the active onion powder in this trial were cultivated in Hokkaido, Japan. White onions did not have detectable levels of quercetin (Table 1) and were used for the placebo powder. The active and placebo powders were manufactured in compliance with the Food Sanitation Act (Ministry of Health, Labour and Welfare of Japan) by Okamoto Plant Breeding Co., Ltd. (Hokkaido, Japan). The manufacturing process of onion powder was the following: peeled onions were soaked in hypochlorous acid solution for 20 min, thoroughly rinsed with water, cut into 2-mm wide pieces, dried at 45°C for 30 h, sterilized at 60°C for 120 min, and finally powderized. The active onion powder contained 'Quergold' and 'Sarasara-gold' at a ratio of 7:9, and the amount of quercetin contained in the active test food was adjusted accordingly. The analytical results of the nutrient composition of the active test and placebo foods used in this study are summarized in Table 1 . The active test and placebo foods were identical in appearance. and short-term memory. In the YKSST, the patient is presented with combinations of kanji characters and symbols. Each subject was then given 2 min to fill in the lower blank boxes with the correct symbols matching the kanji characters written in the upper boxes. The perfect score on the YKSST is 75 points. For the memory recall test, subjects were required to write the names of as many vegetables as they could recall within one min. For the short-term memory test, the subject was first asked to memorize 10 words and to write them down immediately (immediate memory), then approximately 10 min later, the subject had to recall the same words to write them again 
Physical, hematological, and biological examinations
Blood samples were taken for testing at the baseline and at weeks 12 and 24 after the start of the study. In addition to a medical interview by a medical doctor, each subject's body composition (body weight, body mass index, and body fat ratio) and blood pressure (BP) were measured.
General blood tests were performed to measure anti-oxidant marker (ox-LDL) levels, lipid (TG, TC, HDL-C, and LDL-C) levels, glucose metabolism (BG and HbA1c), complete blood counts Tokyo, Japan) and Automatic Blood Pressure Monitor HEM-7080IC (Omron Colin Co., Ltd., Tokyo, Japan), respectively.
Ethics committee
All subjects and their study partners provided written informed consent prior to undergoing any test related to this study. The study protocol was approved by the Ethics Committee of Hokkaido Information University and was in conformity to the Helsinki Declaration (approval date: Dec 1, 2014; approval number: 2014-19). This study was registered with UMIN (approval number: UMIN000015940).
Sample size
The sample size was statistically determined to obtain a power of 80% with an alpha value of 0.05.
In order to demonstrate an effect in the MMSE at 24 weeks after the start of the study, which was postulated to be a 1.00 increase with a standard deviation of 6.00, a sample size of 48 (24 in the active test food group and 24 in the placebo food group) was required. Assuming a 20% loss during follow-up, 60 subjects were selected.
Statistical analysis
Values are presented in the tables as means ± standard deviations. The Mann-Whitney U test was used to evaluate changes in cognitive function. Student's t-test was used to analyze differences in the physical, hematological, and biological parameters between the active test and placebo food groups at each evaluation point. Additionally, to clarify the effects of age on the MMSE and cognitive impairment rating scale scores, we divided the subjects into two subgroups with respect to the median age: younger subject group (subjects <72 years old; 11 subjects in the active test food group and 13 in the placebo food group) and older subject group (subjects ≥72 years old; 14 subjects in the active test food group and 12 in the placebo food group). Statistical analyses were performed using SPSS Statistics 19 (IBM, Armonk, NY, USA). A p-value of <0.05 was considered to be significant, while a p-value of <0.10 was defined as a marginal difference.
RESULTS

Subject dropouts, exclusions and characteristics
During the trial, 10 subjects withdrew due to personal reasons (dropout of study partner, n = 3;
non-participation in examination, n = 2; and difficulty in continuing the trial, n = 5). Consequently, 50 subjects completed this trial (25 subjects in each group). Although some subjects were taking drugs, including anti-allergics, anti-hyperuricemics, and anti-osteoporotics, they did not change their drugs during the study period. Additionally, the number of subjects taking these drugs was not different between the active test and placebo food groups. Moreover, there was one smoker among our subjects. This subject smoked five cigarettes daily and did not change the number of cigarettes smoked per day during the study period. Therefore, we determined that drugs and nicotine/smoking may have not influenced outcome levels on the MSSE. No subject was excluded from the analysis of the "per protocol set." The flow diagram of the study is shown in Figure 2 .
The mean age, height, body weight, body mass index, body fat ratio, years of education, and cognitive impairment rating scale score for each group are presented in Table 2 . These data did not significantly differ between the active test and placebo food groups, confirming the appropriate allocation of subjects in the two groups. Values are shown as the mean ± standard deviation. Analyses were performed using Student's t-test for age, height, body weight, body fat ratio and body mass index, the chi-squared test for gender and Mann-Whitney's U test for the cognitive impairment rating scale and intake rate. n = number of subjects.
Effect of quercetin-rich onions on the MMSE and cognitive impairment rating scale scores
First, we evaluated the effect of quercetin-rich onions on cognitive function using the MMSE ( Figure 3 and Table 3 ). There were no significant differences between the active test and placebo food groups regarding changes in the MMSE scores from the baseline to the other time points ( Figure 3A) . Although there were no significant differences between the active test and placebo food groups in the older subject group (Figure 3C ), in the younger subject group there was a significant difference between the active test and placebo food groups in the change in the MMSE scores from baseline to week 24 (placebo: −0.31 ± 2.10, test: 1.64 ± 2.11, p = 0.019) ( Figure 3B ).
We also examined the effect of quercetin-rich onions on the cognitive impairment rating scale scores ( Figure 4 and Table 3 ). The values did not significantly differ between the active test and placebo food groups as a result of total analysis and subgroup analysis.
Effect of quercetin-rich onions on the NPI-Q-J scores
To confirm the effect of quercetin-rich onions on study partner parameters, we evaluated changes in the two NPI-Q-J indices: "Severity of subject's symptoms" and "Burden on study partner." weeks 12 (change from baseline to week 12: placebo, 0.36 ± 2.38; test, −1.04 ± 2.56; p = 0.067) and 24 (placebo, −0.04 ± 1.49; test, −0.80 ± 1.76; p = 0.060) after the start of the study (Table 3) .
Moreover, compared to the placebo food group, "Burden on study partner" decreased in the active test food group at week 24 (change from baseline to week 24: placebo, 0.08 ± 1.91; test, −0.84 ± 2.27; p = 0.093) after the start of the study (Table 3 ). Inventory-Questionnaire Japanese-language version; ⊿ week 12, change from baseline to weeks 12; ⊿ week 24, change from baseline to weeks 24. *Statistically significant, p < 0.05. #Marginally significant, p < 0.10.
Effect of quercetin-rich onions on lipid metabolism, glucose metabolism, and oxidative parameters
We evaluated the effect of quercetin-rich onions on lipid metabolism, glucose metabolism, and oxidative parameters and discovered no significant differences between the active test and placebo food groups (Table 4) . 
Safety:
We evaluated CBCs, liver and renal function, and BP after the ingestion of quercetin-rich onions. As shown in Table 5 , minimal changes were observed in CBC parameters (WBC count, RBC count, Hb level, Ht, and Plt count), liver function (AST, ALT, γ-GTP, ALP, and LDH), renal function (BUN, CRE, and UA), Alb, TP, and BP. Although few subjects exhibited adverse events, they only had mild symptoms and recovered from these symptoms within a few days. Accordingly, the principal investigator judged that no adverse events were related to the ingestion of the test food. These results suggested that the ingestion of quercetin-rich onions ('Quergold' and 'Sarasara-gold') had no or minimal unfavorable effects, even at a dose of 83 g/day (raw-onion). dysglycemic, and anti-oxidant effects of quercetin-rich onions and the relationship of cognitive function with these parameters.
The NPI-Q-J score improved among subjects who consumed quercetin-rich onions. Notably, irritability was the most improved factor among the subquestions. BPSDs comprise a core set of symptoms in patients with dementia and can be observed before making a diagnosis of clinical dementia [40] . The development of BPSDs is associated with a faster cognitive decline, greater impairment in the activities of daily living, and lower quality of life for patients and caregivers [41] . In our clinical study, study partners answered "no symptoms (0 points)" to most questions because the study subjects were healthy or exhibited MCI. Although further research is needed, these results suggest that quercetin-rich onions improve BPSDs in patients with early stage dementia.
Our clinical trial included healthy or MCI subjects who were not receiving medications for dementia, AD, psychiatric disorders, or cerebrovascular diseases. In the future, we need to investigate the effects of quercetin-rich onions in different types of patients.
CONCLUSION
The results of our present study revealed that quercetin-rich onions had positive effects on cognitive function. Onions are components of the typical diets of elderly people, so we can provide new applications of quercetin-enriched food using quercetin-rich onions. The biological mechanism of these results should be elucidated to fully understand the effects of quercetin-rich onions. Although we demonstrated the effect of quercetin-rich onions on subjects of a particular age group, our results suggested that the intervention of dietary food is required at an early stage to improve cognitive function. Further studies of quercetin-rich onions will be needed to develop new treatment strategies for maintaining cognitive function.
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